Poseida Therapeutics, Inc (PSTX) with a decrease of 35.8%; announced that following notice to the US Food and Drug Administration (FDA) of a halt in registration pursuant to the arrangement to investigate a patient death, it has acquired communication from the FDA regarding the Company’s Stage 1 clinical trial for P-PSMA-101 in metastatic prostate cancer has been placed on hold. 

Cinemark Holdings, Inc (CNK) with a decrease of 4.9% stated today that is plans to launch a private contribution of $400 million aggregate principal amount of convertible notes due by 2025 (the Notes) to individuals reasonably considered to be qualified corporate buyers pursuant to rule 144A under the Securities act of 1933, as revised. 

Krystal Biotech, Inc. (KRYS) with an increase of 3.8%; announced that the US Food and Drug Administration (FDA) has permitted Orphan Drug Destination to KB407, presently in diagnosing advancement for the treatment of cyclist fibrosis (CF) 

Dolphin Entertainment (DLPN) with an increase of 13%; stated a large expansion of its entertainment marketing capacity through its addition of influencer marketing leader, Be Social.